BioCorteX, a start-up based in London, has secured $5 million in seed funding from top investors Hoxton Ventures and Sofinnova Partners. The company's mission is to advance biotechnology research, believing everyone deserves access to effective medications regardless of their background or location.

As a biotechnology research company, BioCorteX is dedicated to developing innovative and effective treatments for various medical conditions. With their seed funding, they aim to expand their research efforts and further develop their cutting-edge technologies.

With a focus on positively impacting global health, BioCorteX is committed to advancing biotechnology research.

Their seed funding will allow them to continue pursuing their mission and bringing new treatments to needy patients. Visit their latest funding round for more information: https://founderlodge.com/round/BioCorteX-raises-5000000-Seed-2023-03-31-Nik-Sharma-MTE3NzE